FP7Реинтеграция2011–2015

STEM CELL IMAGING · Molecular imaging of the myocardium to facilitate cardiac stem cell therapy

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2011-07-01 → 2015-06-30
Финансиране от ЕС
100 000 €
Участници
1
Схема
MC-IRG

Линиите свързват координатора с партньорите.

Накратко на български

Молекулярното изображение на сърцето проследява процеси като метаболизма на глюкозата и възпаленията след увреждане на тъканите. Това помага за определяне на оптималните условия в организма, които да подпомогнат възстановяването на сърдечния мускул чрез терапия със стволови клетки.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Molecular imaging of the myocardium to facilitate cardiac stem cell therapy

The goal of this grant was to develop a molecular imaging platform for noninvasive monitoring of the mechanisms involved in myocardial repair, including cell trafficking and microenvironmental conditions. In a 4-year project, researchers at Hannover Medical School (MHH) tested the central hypothesis that molecular-targeted nuclear imaging of the myocardium permits characterization of an optimal biologic environment that supports tissue recovery. The project completed 3 specific aims in a translational layout: Aim 1 was to determine the role of tissue perfusion and metabolism in the area of myocardial damage for successful subsequent regeneration. Aim 2 was to study the role of neurohumoral activation after ischemic damage for regeneration. And Aim 3 was to translate the knowledge to the clinical setting. For completion of Aim 1, extensive preparation and construction of a new preclinical molecular imaging lab was performed at MHH. Dedicated small animal PET-CT and SPECT-CT scanners were installed to provide optimal conditions for subsequent in vivo imaging work within the project. Next, dedicated imaging protocols for molecular imaging in rodents were established using the new equipment. Initial molecular targets included glucose metabolism, inflammation, perfusion. Specific anesthesia protocols for suppressing physiologic myocardial glucose utilisation in order to target glucose uptake in inflammatory cells without interference from background signal were established. Research collaborations were established for subsequent projects targeting myocardial tissue regeneration. In parallel, clinical radionuclide imaging facilities were set up with high-end imaging technology in order to match the technology used in the preclinical lab and to thereby facilitate translation. Locoregional, national and international collaborations were strengthened in order to enable expanded preclinical work on the topic of inflammation and regeneration, and in order to achieve the goal of translation to the clinical setting. Preclinical work for Aim 2 focused on the myocardial microenvironment and its interaction with stem cell recruitment to the myocardium. Further biologic insights into the inflammatory state of the acutely infarcted myocardium were obtained in a mouse model using radiolabelled amino acid, novel radiotracer targeting the chemokine receptor CXCR4 and a complex imaging assay to specifically track endogenous bone marrow cell trafficking. This work clearly showed that cells from bone marrow contribute to myocardial inflammation and subsequent regeneration and it provided insights into the interaction between host myocardium and systemic hematopoetic organs. Aim 3 finally focused on translating the preclinical knowledge into the clinical setting. The initial focus was on the use of the glucose analogue F-18 deoxyglucose (FDG) for imaging of myocardial inflammation, which had been established in Aim 1 in mice already. Translation was subsequently expanded toward the novel CXCR4-targeted agent, which was also successfully employed in humans after acute myocardial infarction, in order to show activation of cytokine signalling. The entirety of this work provided unique new insights into myocardial regeneration and laid a foundation for implementation in subsequent clinical trials where the delivered imaging techniques may be used for assistance in therapeutic decision making. The ultimate goal of subsequent efforts will be to optimize regenerative therapeutic benefit based on imaging of individual myocardial biology. Contact details of the primary investigator are: Frank M. Bengel, MD, Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany; E-Mail: bengel.frank@mh-hannover.de. The project website is: http://www.mh-hannover.de/27397.html.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

In clinical trials, functional benefits of cell therapy for repair of the damaged heart have been moderate and variable. Frequently, only a small fraction of transplanted cells engrafts in injured myocardium. This limits therapeutic efficacy and may explain variability of results. There is a need for improved understanding of therapeutic mechanisms and for improved selection of candidates. Specific noninvasive imaging techniques, which go beyond assessment of structure and function of the heart, are promising new means for improving cell therapy.In this proposal, we aim at developing image-based strategies to facilitate stem cell engraftment. The myocardial microenvironment is considered to be a critical contributor to engraftment. It constitutes a suitable target for molecular imaging. Our central hypothesis is that molecular-targeted radionuclide imaging prior to cell delivery can characterize an optimal biologic environment which is supportive of cell engraftment after delivery, and thus predictive of successful myocardial regeneration. This hypothesis will be tested in 3 specific aims, using an array of noninvasive imaging techniques to characterize myocardial biology, to track stem cells and to determine functional and structural effects of cell delivery.Aim 1 will define the role of tissue perfusion and viability for successful engraftment of bone-marrow derived stem cells. Aim 2 will investigate the role of neurohumoral activation after ischemic damage for successful cardiac stem cell engraftment. And in aim 3, knowledge derived in a rat model in aims 1 and 2 will be translated to a large animal model and clinical camera systems.These studies will provide unique new insights into myocardial regeneration. They will also deliver imaging techniques for assistance in therapeutic decision making. The ultimate goal of the project is to optimize cell therapeutic benefit based on imaging of individual disease biology.

Оригинален текст от CORDIS (на английски).

Участници

  • MEDIZINISCHE HOCHSCHULE HANNOVER · HannoverКоординаторГермания

Връзки

Данни: CORDIS, © Европейски съюз